Literature DB >> 3091854

Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes.

H T Cuypers, G C Selten, M Zijlstra, R E de Goede, C J Melief, A J Berns.   

Abstract

Clonal selections occurring during the progression of Moloney murine leukemia virus (MuLV)-induced T-cell lymphomas in mice were examined in primary and transplanted tumors by monitoring various molecular markers: proviral integration patterns, MuLV insertions near c-myc and pim-1, and rearrangements of the immunoglobulin heavy chain and beta-chain T-cell receptor genes. The results were as follows. Moloney MuLV frequently induced oligoclonal tumors with proviral insertions near c-myc or pim-1 in the independent clones. Moloney MuLV acted as a highly efficient insertional mutagen, able to activate different (putative) oncogenes in one cell lineage. Clonal selections during tumor progression were frequently marked by the acquisition of new proviral integrations. Independent tumor cell clones exhibited a homing preference upon transplantation in syngeneic hosts and were differently affected by the route of transplantation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091854      PMCID: PMC253921     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Mutation selection and the natural history of cancer.

Authors:  J Cairns
Journal:  Nature       Date:  1975-05-15       Impact factor: 49.962

2.  Chromosome changes (trisomies #15 and 17) associated with tumor progression in leukemias induced by radiation leukemia virus.

Authors:  F Wiener; S Ohno; J Spira; N Haran-Ghera; G Klein
Journal:  J Natl Cancer Inst       Date:  1978-07       Impact factor: 13.506

Review 3.  The sequential analysis of cancer development.

Authors:  E Farber; R Cameron
Journal:  Adv Cancer Res       Date:  1980       Impact factor: 6.242

4.  Conformation of free and of integrated Moloney leukemia virus proviral DNA in preleukemic and leukemic BALB/Mo mice.

Authors:  D Jähner; H Stuhlmann; R Jaenisch
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

5.  Thymus cell migration. Quantitative aspects of cellular traffic from the thymus to the periphery in mice.

Authors:  R G Scollay; E C Butcher; I L Weissman
Journal:  Eur J Immunol       Date:  1980-03       Impact factor: 5.532

6.  Identification of DNA fragments carrying ecotropic proviruses of AKR mice.

Authors:  D Steffen; S Bird; W P Rowe; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

7.  Is trisomy cause or consequence of murine T cell leukemia development? Studies on Robertsonian translocation mice.

Authors:  J Spira; F Wiener; S Ohno; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

8.  Increase of AKR-specific sequences in tumor tissues of leukemic AKR mice.

Authors:  A Berns; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

9.  Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal.

Authors:  R Jaenisch; H Fan; B Croker
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

10.  The integration sites of endogenous and exogenous Moloney murine leukemia virus.

Authors:  H van der Putten; E Terwindt; A Berns; R Jaenisch
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

View more
  21 in total

1.  Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas.

Authors:  J Jonkers; H C Korswagen; D Acton; M Breuer; A Berns
Journal:  EMBO J       Date:  1997-02-03       Impact factor: 11.598

Review 2.  Provirus tagging as an instrument to identify oncogenes and to establish synergism between oncogenes.

Authors:  A Berns
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Frequent involvement of the fim-3 region in Friend murine leukemia virus-induced mouse myeloblastic leukemias.

Authors:  D Bordereaux; S Fichelson; B Sola; P E Tambourin; S Gisselbrecht
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Provirus insertion in Tpl-1, an Ets-1-related oncogene, is associated with tumor progression in Moloney murine leukemia virus-induced rat thymic lymphomas.

Authors:  S E Bear; A Bellacosa; P A Lazo; N A Jenkins; N G Copeland; C Hanson; G Levan; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

5.  Cell transformation and tumor induction by Abelson murine leukemia virus in the absence of helper virus.

Authors:  P L Green; D A Kaehler; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

6.  Activation of int-1 and int-2 mammary oncogenes in hormone-dependent and -independent mammary tumors of GR mice.

Authors:  J Mester; E Wagenaar; M Sluyser; R Nusse
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

7.  Integration of the BALB/c ecotropic provirus into the colony-stimulating factor-1 growth factor locus in a myc retrovirus-induced murine monocyte tumor.

Authors:  W R Baumbach; E M Colston; M D Cole
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Lymphotropic papovavirus early region is specifically regulated transgenic mice and efficiently induces neoplasia.

Authors:  J D Chen; K Neilson; T Van Dyke
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

9.  Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?

Authors:  E W Baxter; K Blyth; L A Donehower; E R Cameron; D E Onions; J C Neil
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Escape from in vivo restriction of Moloney mink cell focus-inducing viruses driven by the Mo+PyF101 long terminal repeat (LTR) by LTR alterations.

Authors:  B K Brightman; C Farmer; H Fan
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.